Back in November 2020, Cassava priced its public offering at $8 per share. Proceeds of $75 million were meant to support the Phase 3 study. Since then, SAVA stock has traded as high as $146, without a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback